Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings

Key Takeaways

• Guggenheim lifts Amgen price target to $351, maintains neutral rating
• TEPEZZA shows 77% proptosis response versus 19.6% placebo
• Subcutaneous injector matches IV efficacy, improves patient convenience
• Phase 3 trial meets primary and multiple secondary endpoints
• Results may boost Amgen’s Q1 earnings expectations

Pulse Analysis

Amgen’s recent Phase 3 data for TEPEZZA arrives at a pivotal moment for the biotech giant. The subcutaneous on‑body injector achieved a 77% reduction in eye bulge, far outpacing the 19.6% placebo response, and delivered statistically significant improvements across diplopia, disease activity scores, and quality‑of‑life measures. By replicating the efficacy of the established intravenous formulation while offering a more convenient delivery method, TEPEZZA positions Amgen to capture a larger share of the thyroid eye disease market, a niche yet growing therapeutic area with limited treatment options.

Guggenheim’s decision to raise its price target to $351 reflects an updated valuation model that incorporates the TEPEZZA read‑through and anticipated Q1 earnings. While the firm retains a Neutral rating, the modest target increase suggests analysts expect the trial’s success to translate into incremental sales and margin expansion, albeit tempered by broader market dynamics such as pricing pressures and competitive pipelines. The timing—just before Amgen’s earnings release—means the market will closely scrutinize revenue guidance, especially for the biotech’s oncology and rare‑disease franchises, to gauge whether TEPEZZA can meaningfully lift top‑line growth.

For investors, the confluence of a strong clinical readout and a revised analyst model underscores the importance of pipeline milestones in biotech valuation. TEPEZZA’s favorable safety profile, characterized mainly by mild injection‑site reactions, reduces regulatory risk and may accelerate commercial rollout. As the sector grapples with heightened scrutiny on drug pricing, a product that combines efficacy with patient convenience could serve as a differentiator, potentially bolstering Amgen’s competitive positioning and supporting a more optimistic earnings outlook. Confidence in the company’s ability to monetize its diversified pipeline will likely influence allocation decisions across biotech‑focused portfolios.